Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Recently approved xanomeline and trospium chloride (Cobenfy ...

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of ...

Relative to placebo, lumateperone significantly improved MADRS, CGI-S, and QIDS-SR-16 scores by day 43 among patients with MDD.

Presentations include results from two pivotal studies (Studies 501 and 502) evaluating lumateperone as an adjunctive therapy to antidepressants ...

For the CGI-S scale, at the end of treatment ... the outcome of all-cause time to discontinuation in the treatment of schizophrenia as a proxy measure for treatment effectiveness (primary efficacy ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center ...

the Clinical Global Impression-Severity (CGI-S) scale at week five and percentage of PANSS responders at week five compared to placebo. Key secondary endpoints were formally tested sequentially in ...

Both studies also met the key secondary endpoint (CGI-S) and showed statistically ... depression and in our open-label safety study in schizophrenia and bipolar disorder in pediatric patients.